Explore licensed vaccines, adverse event reporting data, and history for this disease.
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Not Filed / Pre-submission |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Scientific Profile & Documentation
- Platform Architecture
- Conjugate vaccine
- Lead Developer
- Sinovac Life Sciences Co., Ltd.
- Next Expected Milestone
- Primary completion (most advanced trial): 2026-05-12 (registry estimate)
- Analyst & Development Notes
- Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
- Primary Source Documentation
- ClinicalTrials.gov NCT06617715 →
- Additional Sources & Literature
- NCT07593924 on ClinicalTrials.gov (2026-07-10)
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
Milestone Overview
-
Stage VerificationPhase 3 Clinical Trial confirmed as of 2026-07-10.
-
Target MilestonePrimary completion (most advanced trial): 2026-05-12 (registry estimate)
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.